> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Myriad Genetics Will Pay Former Commercial Chief Brian Donnelly $1,322,294 In Severance, 8-K Shows
- URL: https://www.bullished.co/myriad-genetics-will-pay-former-commercial-chief-brian-donnelly-1-322-294-in-severance-8-k-acb68dbe/
- Published: 2026-10-09T20:36:30.000Z
- Updated: 2026-10-09T20:36:30.000Z
- Description: The payout comes with two years of equity vesting treatment and takes effect October 14 unless Donnelly revokes the agreement.
- Author: Matteo Parrino
- Tags: SEC Filings, MYGN, Industry: Healthcare

Myriad Genetics agreed to pay Brian Donnelly, its former Chief Commercial Officer, a [lump sum of $1,322,294](https://www.sec.gov/Archives/edgar/data/0000899923/000089992326000084/mygn-20261006.htm?ref=bullished.co) in severance, according to an 8-K filed Friday. The company signed the separation agreement with him on Tuesday.

## What the 8-K says

The filing describes a Separation Agreement and Release of Claims dated October 6\. In exchange, Donnelly commits to restrictive covenants, including what the filing calls customary non-solicitation and non-disparagement terms, and gives a release of claims against the company.

Donnelly left the Chief Commercial Officer role effective September 16, the filing says, and the company notes this was previously disclosed. His employment ended at the close of business on September 21, which the agreement treats as his separation date.

The severance and other consideration are paid under Donnelly's existing Severance and Change of Control Agreement, the filing says.

## How his equity awards are treated

Two things happen to his equity, both measured over the two years after the September 21 separation date.

- Time-based awards that were scheduled to vest within those two years are accelerated and deemed to vest on the separation date, with any annual installments deemed to vest in monthly installments over the period.
- Awards carrying an unmet performance condition stay outstanding, and vest only if the condition is met within the two years, and only for the portion scheduled to vest in that window.

The filing gives no share counts or dollar value for these awards.

## What to watch

The agreement becomes effective on October 14, provided Donnelly does not revoke it before then. The full text is [attached to the 8-K](https://www.sec.gov/Archives/edgar/data/0000899923/000089992326000084/mygn-20261006.htm?ref=bullished.co) as Exhibit 10.1.

The next date that matters is October 14, when the agreement takes effect if Donnelly has not revoked it.

### Sources

- [8-K Filing — MYRIAD GENETICS INC (MYGN)](https://www.sec.gov/Archives/edgar/data/0000899923/000089992326000084/mygn-20261006.htm?ref=bullished.co) — SEC EDGAR